Overcoming Chemotherapy Resistance

• 3101 · PDF Identification and characterization of novel peptide binders against platinum resistant epithelial ovarian cancer Pritha Ray, Sreyashi Nath, Pranita Uttamrao Patil, Parijat Das, Prasenjit Bhaumik
• 3102 · PDF YB-1 small-molecule inhibitor improves chemotherapy success in treating high-grade serous ovarian carcinoma Dhanir Tailor, Fernando J. Garcia-Marques, Abel Bermudez, Wenqi Li, Annah Rolig, Chia-Feng Tsai, Tao Liu, Tanja Pejovic, Sharon Pitteri, Sanjay V. Malhotra
• 3103 · PDF Spatial proteomics reveals vasculature and immune modulation for overcoming doxorubicin resistance in breast cancer Gautami Gaidhani, Juraj Jakubik, Leoni Moldaner, Yishu Xu, Zuzana Tatarova
• 3104 Characterization of high plasticity cell states in cutaneous squamous cell carcinoma in response to chemotherapy and immune checkpoint inhibitor treatments Ramin Farhad, Di Wu, Mark A. Taylor, Allan Balmain, Rosemary J. Akhurst
• 3105 MalforminA1 reverts cisplatin resistance by modulating oncogenic signaling pathways in ovarian cancer Yahya Tamimi, Aikou Okamoto, Ikram Burney
• 3106 · PDF OC201 and OC202e, an AI-driven drug combination, enhance the susceptibility of pancreatic cancer to FOLFIRINOX by modulating HIF-1alpha Yongjin Kim, Sewon Kim, Dong Sub Jung, So Jung Sung, Yenny Kim, Ki Sung Song, Hyemin Won, Yi Rang Kim, Jihoon Kang
• 3107 · PDF CWH43 emerges as a novel therapeutic target linked to chemoresistance in colorectal cancer Yu-Jia Chang, Chien-Yu Huang, Po-Li Wei, Cheng-Chin Lee
• 3108 · PDF LEDGF/p75 drives chemoresistance in CML via JAK/STAT pathway modulation Thatcher Akele, Cecilia Iglesias-Herrero, Frauke Christ, Zeger Debyser
• 3109 · PDF Extracellular matrix glycan signatures predict chemotherapy response in ovarian cancer Erica J. Peterson, Ryan J. Weiss, James D. Hampton, Ava R. S. Beaudin, Thomas M. Clausen, Joseph B. M. Turner, Amrita Basu, Bin Hu, Jennifer E. Koblenski, Nicholas P. Farrell, Larisa Litovchick
• 3110 · PDF Targeting LIF/LIFR signaling with EC359 overcomes chemoresistance and enhances chemotherapy efficacy in ovarian cancer Sonal R. Chaudhari, Baskaran Subramani, Gaurav Sharma, William Cole Arnold, Durga Meenakshi Panneerdoss, Edward R. Kost, Bindhu Santhamma, Hareesh B. Nair, Suryavathi Viswanadhapalli, Ratna K. Vadlamudi
• 3111 · PDF Pancreatic cancer cells elevate NAD+production in response to nutrient limitation and chemotherapeutic stress Faith Nakazzi, Mehrdad Zarei, Mariana Lopes, Hallie J. Graor, William C. Beegan, Eric Gu, Sakineh Rezaei, Peder J. Lund, Jordan M. Winter
• 3112 · PDF Targeting chemoresistance in ovarian cancer Dhanamjai Penta, Vishal Chandra, Lauren Dockery, Rajani Rai
• 3113 · PDF Chronic type 1 interferon exposure phenocopies chronic cisplatin exposure in high grade serous ovarian cancer Ashlyn Conant, Kiera McGivney, Tise Suzuki, Sharon Asariah, Brigitte Vazquez, Jay Deng, HyeonJoo Cheon, Juli Unternaehrer
• 3115 RTF2 drives oxaliplatin resistance in colorectal cancer by promoting phase separation-mediated homologous recombination repair Yiran Bie, Chong Chen, Haiqin Jiang, Zhizhong Xiong, Bin Zhong, Haoyang Xv, Yufeng Chen, Lei Lian, Xiaojian Wu, Peishan Hu
• 3116 · PDF CDK4/6 inhibition overcomes 5-FU resistance by suppressing TYMS-driven R-loop-associated DNA damage in colorectal cancer Lingling Xu, jiabei zhu, Jinghua Sun, Man Li, Ajay Goel
• 3117 · PDF Defining the role of nucleolar stress in mediating DDB2 induced oxaliplatin resistance in colorectal cancer Vinod Kumar, Dennis Hsu, Orlando D. Schärer, Matthew A. Schaich, Katherine E. Helfrich, Simon C. Watkins, Bennett Van Houten
• 3118 · PDF Dichloroacetate reprograms metabolism and disrupts ROS adaptation, attenuating stemness to reverse chemoresistance in ovarian cancer Yen Thi Do, Seungmee Lee, Shin-Wha Lee, Eun Ji Nam, Jin-Young Kim, Sojin Shin, Ji Hae Seo
• 3119 Modeling chemotherapy persistence in colorectal cancer using patient-derived organoids Yasmine Abouleila, Timo Voskuilen, Mayke Doorn, Roel Verkerk, Jasmin Pourfarzad, Joris Maas, Robert G. J. Vries, Sylvia F. Boj
• 3120 · PDF Using genome wide CRISPR screening to identify synthetic lethal targets for overcoming chemoresistance in rhabdomyosarcoma Aqsa Mazhar, Qian Wang, Satyanarayana Gadde, Daenikka Ravindraraja, Belamy B. Cheung, Glenn Marshall
• 3121 · PDF METTL7B-driven m6A RNA methylation promotes gemcitabine resistance and tumor progression in pancreatic ductal adenocarcinoma Tung-Wei Hsu, Wan-Yu Wang, Yen-Hao Su, Chih-Ming Su, Po-Chen Tseng, Hsin-An Chen
• 3122 · PDF Integrative multi-omic investigation of gene regulatory networks associated with chemotherapy response in acute lymphoblastic leukemia Kelly R. Barnett, Robert J. Mobley, Wenjian Yang, Landon Choi, Kami Chauncy, Kristine R. Crews, Samuel W. Brady, Jun J. Yang, Daniel Savic
• 3123 · PDF Metabolic reprogramming via statin repurposing: A strategy to reverse the Warburg effect and overcome gemcitabine resistance in pancreatic ductal adenocarcinoma Takayuki Noma, Mitsuo Shimada, Ajay Goel
• 3124 · PDF SRSF1 orchestrates splicing-directed dual-engine glucose metabolism driving chemoresistance in diabetes-associated pancreatic cancer Zu-Wei Wang, Yi-Ting Chen, Jin-Peng Lu, Shun-Can Zhu, Hong-Yi Lin, Yin-Hao Chen, Hao-Xiang Zhang, Shi Chen
• 3125 · PDF Transcriptomic analysis of glycosylation genes in chemotherapeutic-resistant glioma cells Vi P. Dang, Nicole S. Lav, Alan Y. L. Jiang, Jaclyn N. Hanamoto, Daniela A. Bota, Lisa A. Flanagan
• 3127 · PDF Overcoming chemoresistance: Restoring doxorubicin sensitivity and natural killer cell immunity in resistant DLBCL cells through reduction of endoplasmic reticulum stress Yi-Cheng Lin, Chih-Chi Andrew Hu, Chih-Hang A. Tang, Chun-Yu Cheryl Chuang, Chiung-Tong Chen
• 3128 · PDF IDH1 inhibition potentiates gemcitabine efficacy in pancreatic ductal adenocarcinoma Yuan Li, Wenhao Weng, Ajay Goel
• 3129 Proteasome-associated DUB inhibition by VLX1570 targets UCHL5/USP14 and enhances cisplatin efficacy in neuroblastoma Yi Ju Kao, Kuan-Lin Kuo, Chen-Hsun Hsu, Shih-Ming Liao, Po-Ming Chow, Kuo-How Huang

在完整检索应用中浏览本分会场 →